Synergy between the KEAP1/NRF2 and PI3K Pathways Drives Non-Small-Cell Lung Cancer with an Altered Immune Microenvironment

R: A Language and Environment for Statistical Computing

R Core Team (2000) · doi:10.32614/r.manuals · Cited by 355,706 · see citing works

Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing

Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482 · see citing works

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625 · see citing works

limma powers differential expression analyses for RNA-sequencing and microarray studies

Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458 · see citing works

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data

Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455 · see citing works

Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160 · see citing works

The blockade of immune checkpoints in cancer immunotherapy

Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · see citing works

A scaling normalization method for differential expression analysis of RNA-seq data

Robinson, M. D., & Oshlack, A. (2010) · Genome Biology · doi:10.1186/gb-2010-11-3-r25 · Cited by 7,876 · see citing works

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802 · see citing works

voom: precision weights unlock linear model analysis tools for RNA-seq read counts

Law, C. W., Chen, Y., Shi, W., & Smyth, G. K. (2014) · Genome Biology · doi:10.1186/gb-2014-15-2-r29 · Cited by 6,155 · see citing works

Comprehensive molecular profiling of lung adenocarcinoma

The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732 · see citing works

xCell: digitally portraying the tissue cellular heterogeneity landscape

Aran, D., Hu, Z., & Butte, A. J. (2017) · Genome Biology · doi:10.1186/s13059-017-1349-1 · Cited by 4,397 · see citing works

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., Schrock, A., Campbell, B., Shlien, A., Chmielecki, J., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0424-2 · Cited by 3,519 · see citing works

Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus

Srinivas, S., Watanabe, T., Lin, C.-S., William, C. M., Tanabe, Y., Jessell, T. M., & Costantini, F. (2001) · BMC Developmental Biology · doi:10.1186/1471-213x-1-4 · Cited by 3,121 · see citing works

Regulation of inflammation by short chain fatty acids

Vinolo, M. A. R., Rodrigues, H. G., Nachbar, R. T., & Curi, R. (2011) · Nutrients · doi:10.3390/nu3100858 · Cited by 1,724 · see citing works

Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming

Mitsuishi, Y., Taguchi, K., Kawatani, Y., Shibata, T., Nukiwa, T., Aburatani, H., Yamamoto, M., & Motohashi, H. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.016 · Cited by 1,395 · cited 6× · see citing works

Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

Akbay, E. A., Koyama, S., Carretero, J., Altabef, A. B., Tchaicha, J. H., Christensen, C. L., Mikse, O. R., Cherniack, A. D., Beauchamp, E. M., Pugh, T. J., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0310 · Cited by 1,237 · see citing works

Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses

Lavin, Y., Kobayashi, S., Leader, A., Amir, E.-A. D., Elefant, N., Bigenwald, C., Remark, R., Sweeney, R., Becker, C. D., Levine, J. H., et al. (2017) · Cell · doi:10.1016/j.cell.2017.04.014 · Cited by 1,209 · see citing works

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

Hellmann, M. D., Rizvi, N. A., Goldman, J. W., Gettinger, S. N., Borghaei, H., Brahmer, J. R., Ready, N. E., Gerber, D. E., Chow, L. Q., Juergens, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30624-6 · Cited by 962 · see citing works

Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy

Pfirschke, C., Engblom, C., Rickelt, S., Cortez‐Retamozo, V., Garris, C., Pucci, F., Yamazaki, T., Poirier-Colame, V., Newton, A., Redouane, Y., et al. (2016) · Immunity · doi:10.1016/j.immuni.2015.11.024 · Cited by 944 · see citing works

Camera: a competitive gene set test accounting for inter-gene correlation

Wu, D., & Smyth, G. K. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks461 · Cited by 880 · see citing works

Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase

DuPage, M. J. P., Dooley, A. L., & Jacks, T. (2009) · Nature Protocols · doi:10.1038/nprot.2009.95 · Cited by 862 · see citing works

Negative Regulation of Neural Stem/Progenitor Cell Proliferation by the <i>Pten</i> Tumor Suppressor Gene in Vivo

Groszer, M., Erickson, R., Scripture-Adams, D. D., Lesche, R., Trumpp, A., Zack, J. A., Kornblum, H. I., Liu, X., & Wu, H. (2001) · Science · doi:10.1126/science.1065518 · Cited by 798 · see citing works

Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis

Romero, R., Sayin, V. I., Davidson, S. M., Bauer, M. R., Singh, S. X., LeBoeuf, S. E., Karakousi, T. R., Ellis, D. C., Bhutkar, A., Sánchez-Rivera, F. J., et al. (2017) · Nature Medicine · doi:10.1038/nm.4407 · Cited by 652 · see citing works

The Dual Roles of NRF2 in Cancer

Menegon, S., Columbano, A., & Giordano, S. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.05.002 · Cited by 633 · see citing works

The Differential Effects of Mutant <i>p53</i> Alleles on Advanced Murine Lung Cancer

Jackson, E. L., Olive, K. P., Tuveson, D. A., Bronson, R., Crowley, D., Brown, M., & Jacks, T. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2193 · Cited by 553 · see citing works

Notch-Dependent Differentiation of Adult Airway Basal Stem Cells

Rock, J. R., Gao, X., Xue, Y., Randell, S. H., Kong, Y., & Hogan, B. L. M. (2011) · Cell stem cell · doi:10.1016/j.stem.2011.04.003 · Cited by 459 · see citing works

Nrf2 and Keap1 Abnormalities in Non–Small Cell Lung Carcinoma and Association with Clinicopathologic Features

Solis, L. M., Behrens, C., Dong, W., Suraokar, M. B., Ozburn, N. C., Moran, C. A., Corvalán, A. H., Biswal, S. S., Swisher, S. G., Bekele, B. N., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3352 · Cited by 430 · see citing works

The Keap1–Nrf2 system in cancers: stress response and anabolic metabolism

Mitsuishi, Y., Motohashi, H., & Yamamoto, M. P. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00200 · Cited by 394 · see citing works

Loss of Lkb1 and Pten Leads to Lung Squamous Cell Carcinoma with Elevated PD-L1 Expression

Xu, C., Brainson, C. F., Koyama, S., Wu, H., Zhao, Y., Chen, Z., Herter-Sprie, G. S., Akbay, E. A., Tchaicha, J. H., Altabef, A. B., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.033 · Cited by 394 · see citing works

Plasticity of Hopx(+) type I alveolar cells to regenerate type II cells in the lung

Jain, R., Barkauskas, C. E., Takeda, N., Bowie, E. J., Aghajanian, H., Wang, Q., Padmanabhan, A., Manderfield, L. J., Gupta, M., Li, D., et al. (2015) · Nature Communications · doi:10.1038/ncomms7727 · Cited by 303 · see citing works

Multiple cells-of-origin of mutant K-Ras–induced mouse lung adenocarcinoma

Sutherland, K. D., Song, J., Kwon, M. C., Proost, N., Zevenhoven, J., & Berns, A. J. M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1319963111 · Cited by 267 · see citing works

SOX2 Is the Determining Oncogenic Switch in Promoting Lung Squamous Cell Carcinoma from Different Cells of Origin

Ferone, G., Song, J., Sutherland, K. D., Bhaskaran, R., Monkhorst, K., Lambooij, J.-P., Proost, N., Gargiulo, G., & Berns, A. J. M. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.09.001 · Cited by 244 · see citing works

Ionizing Radiation Activates the Nrf2 Antioxidant Response

McDonald, J., Kim, K., Norris, A. J., Vlashi, E., Phillips, T. M., Lagadec, C. H., Donna, L. D., Ratikan, J. A., Szelag, H., Hlatky, L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0171 · Cited by 224 · see citing works

HBO1 Is Required for H3K14 Acetylation and Normal Transcriptional Activity during Embryonic Development

Kueh, A. J., Dixon, M. P., Voss, A. K., & Thomas, T. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.00159-10 · Cited by 189 · see citing works

Combining multiple tools outperforms individual methods in gene set enrichment analyses

Alhamdoosh, M., Ng, M., Wilson, N. J., Sheridan, J. M., Huynh, H., Wilson, M. J., & Ritchie, M. E. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw623 · Cited by 178 · see citing works

RTCGAToolbox: A New Tool for Exporting TCGA Firehose Data

Samur, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106397 · Cited by 160 · see citing works

Emerging role of NRF2 in chemoresistance by regulating drug-metabolizing enzymes and efflux transporters

Bai, X., Chen, Y., Hou, X., Huang, M., & Jin, J. (2016) · Drug Metabolism Reviews · doi:10.1080/03602532.2016.1197239 · Cited by 159 · see citing works

Deletion of Keap1 in the Lung Attenuates Acute Cigarette Smoke–Induced Oxidative Stress and Inflammation

Blake, D. J., Singh, A., Kombairaju, P., Malhotra, D., Mariani, T. J., Tuder, R. M., Gabrielson, E. W., & Biswal, S. S. (2009) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2009-0054oc · Cited by 150 · see citing works

Biomarkers for PD-1/PD-L1 Blockade Therapy in Non–Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?

Chae, Y. K., Pan, A. P., Davis, A. A., Raparia, K., Mohindra, N. A., Matsangou, M., & Giles, F. J. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.03.011 · Cited by 113 · see citing works

The Impact of Genomic Changes on Treatment of Lung Cancer

Cardarella, S., & Johnson, B. E. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201305-0843pp · Cited by 103 · see citing works

Nrf2 Enhances Cholangiocyte Expansion in Pten-Deficient Livers

Taguchi, K., Hirano, I., Itoh, T., Tanaka, M., Miyajima, A., Suzuki, A., Motohashi, H., & Yamamoto, M. P. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.01384-13 · Cited by 98 · see citing works

Detection of Lung Cancer through Metabolic Changes Measured in Blood Plasma

Louis, E., Adriaensens, P., Guedens, W., Bigirumurame, T., Baeten, K., Vanhove, K., Vandeurzen, K., Darquennes, K., Vansteenkiste, J., Dooms, C., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.01.011 · Cited by 73 · see citing works

Differential Regulation of MUC5AC/Muc5ac and hCLCA-1/mGob-5 Expression in Airway Epithelium

Thai, P., Chen, Y., Dolganov, G., & Wu, R. (2005) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2004-0220rc · Cited by 70 · see citing works

Conditional Deletion of Pten Causes Bronchiolar Hyperplasia

Davé, V., Wert, S. E., Tanner, T. N., Thitoff, A. R., Loudy, D. E., & Whitsett, J. A. (2007) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2007-0182oc · Cited by 29 · see citing works

Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases

Cuadrado, A., Rojo, A. I., Wells, G., Hayes, J. D., Cousin, S. P., Rumsey, W. L., Attucks, O. C., Franklin, S., Levonen, A., Kensler, T. W., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0008-x · Cited by 1,474 · see citing works

The lung microenvironment: an important regulator of tumour growth and metastasis

Altorki, N. K., Markowitz, G. J., Gao, D., Port, J. L., Saxena, A., Stiles, B. M., McGraw, T. E., & Mittal, V. (2018) · Nature reviews. Cancer · doi:10.1038/s41568-018-0081-9 · Cited by 1,147 · see citing works

Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy

Skoulidis, F., & Heymach, J. V. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0179-8 · Cited by 1,019 · see citing works

Microbiota-Derived Short-Chain Fatty Acids Promote the Memory Potential of Antigen-Activated CD8+ T Cells

Bachem, A., Makhlouf, C., Binger, K. J., de Souza, D. P., Tull, D., Hochheiser, K., Whitney, P. G., Fernandez-Ruiz, D., Dähling, S., Kastenmüller, W., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.06.002 · Cited by 702 · see citing works

The Complex Interplay between Antioxidants and ROS in Cancer

Harris, I. S., & DeNicola, G. M. (2020) · Trends in Cell Biology · doi:10.1016/j.tcb.2020.03.002 · Cited by 638 · see citing works

Quantification of microenvironmental metabolites in murine cancers reveals determinants of tumor nutrient availability

Sullivan, M. R., Danai, L. V., Lewis, C. A., Chan, S. H., Gui, D. Y., Kunchok, T., Dennstedt, E. A., Vander Heiden, M. G., & Muir, A. (2019) · eLife · doi:10.7554/elife.44235 · Cited by 588 · see citing works

BACH1 Stabilization by Antioxidants Stimulates Lung Cancer Metastasis

Wiel, C., Le Gal, K., Ibrahim, M. X., Jahangir, C. A., Kashif, M., Yao, H., Ziegler, D. V., Xu, X., Ghosh, T., Mondal, T., et al. (2019) · Cell · doi:10.1016/j.cell.2019.06.005 · Cited by 579 · see citing works

Diminished efficacy of programmed death-(ligand)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status

Ricciuti, B., Arbour, K. C., Lin, J. J., Vajdi, A., Vokes, N., Hong, L., Zhang, J., Tolstorukov, M. Y., Li, Y. Y., Spurr, L. F., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.10.013 · Cited by 394 · see citing works

The KEAP1-NRF2 pathway: Targets for therapy and role in cancer

Adinolfi, S., Patinen, T., Deen, A. J., Pitkänen, S., Härkönen, J., Kansanen, E., Küblbeck, J., & Levonen, A. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102726 · Cited by 301 · see citing works

Battling Chemoresistance in Cancer: Root Causes and Strategies to Uproot Them

Ramos, A., Sadeghi, S., & Tabatabaeian, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179451 · Cited by 298 · see citing works

The Role of Nrf2 Activity in Cancer Development and Progression

Zimța, A., Cenariu, D., Irimie, A., Magdo, L., Nabavi, S. M., Atanasov, A. G., & Berindan‐Neagoe, I. (2019) · Cancers · doi:10.3390/cancers11111755 · Cited by 298 · see citing works

Ubiquitination: Friend and foe in cancer

Mansour, M. A. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2018.06.001 · Cited by 273 · see citing works

Advances and challenges in therapeutic targeting of NRF2

Dinkova‐Kostova, A. T., & Copple, I. M. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.12.003 · Cited by 272 · see citing works

Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment

Kerk, S. A., Papagiannakopoulos, T. Y., Shah, Y. M., & Lyssiotis, C. A. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00375-9 · Cited by 238 · see citing works

KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden

Marinelli, D., Mazzotta, M., Scalera, S., Terrenato, I., Sperati, F., D'Ambrosio, L., Pallocca, M., Corleone, G., Krasniqi, E., Pizzuti, L., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2105 · Cited by 217 · see citing works

Recent Advances of Natural Polyphenols Activators for Keap1‐Nrf2 Signaling Pathway

Zhou, Y., Jiang, Z., Lu, H., Xu, Z., Tong, R., Shi, J., & Jia, G. (2019) · Chemistry & Biodiversity · doi:10.1002/cbdv.201900400 · Cited by 220 · see citing works

An Overview of the Nrf2/ARE Pathway and Its Role in Neurodegenerative Diseases

Zgórzyńska, E., Dziedzic, B., & Walczewska, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179592 · Cited by 207 · see citing works

Human DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis

Nassar, Z. D., Mah, C. Y., Dehairs, J., Burvenich, I. J. G., Irani, S., Centenera, M. M., Helm, M., Shrestha, R. K., Moldovan, M. V., Don, A. S., et al. (2020) · eLife · doi:10.7554/elife.54166 · Cited by 199 · see citing works

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

Skoulidis, F., Araujo, H. A., Do, M. T., Qian, Y., Sun, X., Galan-Cobo, A., Le, J. T., Montesion, M., Palmer, R., Jahchan, N., et al. (2024) · Nature · doi:10.1038/s41586-024-07943-7 · Cited by 194 · see citing works

The roles of glucose metabolic reprogramming in chemo- and radio-resistance

Lin, J., Xia, L., Liang, J., Han, Y., Wang, H., Oyang, L., Tan, S., Tian, Y., Rao, S., Chen, X., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1214-z · Cited by 191 · see citing works

3D Culture Models with CRISPR Screens Reveal Hyperactive NRF2 as a Prerequisite for Spheroid Formation via Regulation of Proliferation and Ferroptosis

Takahashi, N., Cho, P., Selfors, L. M., Kuiken, H. J., Kaul, R., Fujiwara, T., Harris, I. S., Zhang, T., Gygi, S. P., & Brugge, J. S. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.10.010 · Cited by 186 · see citing works

NRF2: KEAPing Tumors Protected

Pillai, R., Hayashi, M., Zavitsanou, A.-M., & Papagiannakopoulos, T. Y. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0922 · Cited by 187 · see citing works

Glutaminase inhibition impairs CD8 T cell activation in STK11-/Lkb1-deficient lung cancer

Best, S. A., Gubser, P. M., Sethumadhavan, S., Kersbergen, A. J., Abril, Y. L. N., Goldford, J. E., Sellers, K., Abeysekera, W., Garnham, A. L., McDonald, J. A., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.04.003 · Cited by 184 · see citing works

Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations

Remón, J., Passiglia, F., Ahn, M., Barlési, F., Forde, P. M., Garon, E. B., Gettinger, S. N., Goldberg, S. B., Herbst, R. S., Horn, L., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.03.006 · Cited by 168 · see citing works

NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes

Singh, A., Daemen, A., Nickles, D., Jeon, S., Foreman, O., Sudini, K. R., Gnad, F., Lajoie, S., Gour, N., Mitzner, W., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1985 · Cited by 169 · see citing works

Targeting NRF2 and Its Downstream Processes: Opportunities and Challenges

Torrente, L., & DeNicola, G. M. (2021) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-052220-104025 · Cited by 168 · see citing works

Recent Findings in the Regulation of Programmed Death Ligand 1 Expression

Shen, X., Zhang, L., Li, J., Li, Y., Wang, Y., & Xu, Z. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01337 · Cited by 131 · see citing works

Regulation of antioxidants in cancer

Hecht, F., Zocchi, M., Alimohammadi, F., & Harris, I. S. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.11.001 · Cited by 135 · see citing works

Proteasome Activation as a New Therapeutic Approach To Target Proteotoxic Disorders

Njomen, E., & Tepe, J. J. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00101 · Cited by 129 · see citing works

Recent updates on cancer immunotherapy

Liu, M., & Guo, F. (2018) · Precision Clinical Medicine · doi:10.1093/pcmedi/pby011 · Cited by 129 · see citing works

Integrative clinical and molecular characterization of translocation renal cell carcinoma

Bakouny, Z., Sadagopan, A., Ravi, P. K., Metaferia, N. Y., Li, J., AbuHammad, S., Tang, S., Denize, T., Garner, E. R., Gao, X. Y., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2021.110190 · Cited by 123 · see citing works

Role of NRF2 in Lung Cancer

Sánchez-Ortega, M., Carrera, A. C., & Garrido, A. (2021) · Cells · doi:10.3390/cells10081879 · Cited by 124 · see citing works

Distinct initiating events underpin the immune and metabolic heterogeneity of KRAS-mutant lung adenocarcinoma

Best, S. A., Ding, S., Kersbergen, A., Dong, X., Song, J.-Y., Xie, Y., Reljic, B., Li, K., Vince, J. E., Rathi, V., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12164-y · Cited by 108 · see citing works

Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non–Small Cell Lung Cancer

Aggarwal, C., Thompson, J. C., Chien, A. L., Quinn, K., Hwang, W., Black, T. A., Yee, S. S., Christensen, T. E., Lariviere, M. J., Silva, B. A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3663 · Cited by 102 · see citing works

Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases

Volckmar, A., Leichsenring, J., Kirchner, M., Christopoulos, P., Neumann, O., Budczies, J., de Oliveira, C. M. M., Rempel, E., Buchhalter, I., Brandt, R., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32133 · Cited by 102 · see citing works

Regulating Nrf2 activity: ubiquitin ligases and signaling molecules in redox homeostasis

Hayes, J. D., Naidu, S. D., & Dinkova‐Kostova, A. T. (2025) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2024.12.010 · Cited by 94 · see citing works

“NRF2 addiction” in lung cancer cells and its impact on cancer therapy

Hammad, A., Namani, A., Elshaer, M., Wang, X. J., & Tang, X. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.09.016 · Cited by 88 · see citing works

New insights into the role of the Nrf2 signaling pathway in green tea catechin applications

Talebi, M., Talebi, M., Farkhondeh, T., Mishra, G., İlgün, S., & Samarghandian, S. (2021) · Phytotherapy Research · doi:10.1002/ptr.7033 · Cited by 87 · see citing works

Loss-of-function mutations in KEAP1 drive lung cancer progression via KEAP1/NRF2 pathway activation

Gong, M., Li, Y., Ye, X., Zhang, L., Wang, Z., Xu, X., Shen, Y., & Zheng, C. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00568-z · Cited by 86 · see citing works

Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma

Goeman, F., Nicola, F. D., Scalera, S., Sperati, F., Gallo, E., Ciuffreda, L., Pallocca, M., Pizzuti, L., Krasniqi, E., Barchiesi, G., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.07.003 · Cited by 86 · see citing works

NRF2 and the Ambiguous Consequences of Its Activation during Initiation and the Subsequent Stages of Tumourigenesis

Robertson, H., Dinkova‐Kostova, A. T., & Hayes, J. D. (2020) · Cancers · doi:10.3390/cancers12123609 · Cited by 83 · see citing works

Dissecting the Crosstalk between NRF2 Signaling and Metabolic Processes in Cancer

DeBlasi, J. M., & DeNicola, G. M. (2020) · Cancers · doi:10.3390/cancers12103023 · Cited by 80 · see citing works

Clinical Implications of KEAP1-NFE2L2 Mutations in NSCLC

Hellyer, J. A., Padda, S. K., Diehn, M., & Wakelee, H. A. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.11.015 · Cited by 80 · see citing works

Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in KEAP1 mutant lung cancer

Pillai, R., LeBoeuf, S. E., Hao, Y., New, C., Blum, J. L. E., Rashidfarrokhi, A., Huang, S. M., Bahamon, C., Wu, W., Karadal-Ferrena, B., et al. (2024) · Science Advances · doi:10.1126/sciadv.adm9859 · Cited by 79 · see citing works

NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in HER2 -Amplified Gastric Cancer

Gambardella, V., Gimeno-Valiente, F., Tarazona, N., Martínez‐Ciarpaglini, C., Roda, D., Fleitas, T., Tolosa, P., Cejalvo, J. M., Huerta, M., Roselló, S., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2421 · Cited by 75 · see citing works

Battles against aberrant KEAP1-NRF2 signaling in lung cancer: intertwined metabolic and immune networks

Xu, K., Ma, J., Hall, S. R. R., Peng, R., Yang, H., & Yao, F. (2023) · Theranostics · doi:10.7150/thno.80184 · Cited by 75 · see citing works

KEAP1-Mutant NSCLC: The Catastrophic Failure of a Cell-Protecting Hub

Scalera, S., Mazzotta, M., Cortile, C., Krasniqi, E., Maria, R. D., Cappuzzo, F., Ciliberto, G., & Maugeri‐Saccà, M. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.03.011 · Cited by 74 · see citing works

lncRNA‐encoded pep‐AP attenuates the pentose phosphate pathway and sensitizes colorectal cancer cells to Oxaliplatin

Wang, X., Zhang, H., Yin, S., Yang, Y., Yang, H., Yang, J., Zhou, Z., Li, S., Ying, G., & Ba, Y. (2021) · EMBO Reports · doi:10.15252/embr.202153140 · Cited by 71 · see citing works

Activated PKB/GSK-3β synergizes with PKC-δ signaling in attenuating myocardial ischemia/reperfusion injury via potentiation of NRF2 activity: Therapeutic efficacy of dihydrotanshinone-I

Zeng, H., Wang, L., Zhang, J., Pan, T. S., Yu, Y., Lu, J., Zhou, P., Yang, H. Q., & Li, P. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.09.006 · Cited by 73 · see citing works

KEAP1 and TP53 Frame Genomic, Evolutionary, and Immunologic Subtypes of Lung Adenocarcinoma With Different Sensitivity to Immunotherapy

Scalera, S., Mazzotta, M., Corleone, G., Sperati, F., Terrenato, I., Krasniqi, E., Pizzuti, L., Barba, M., Vici, P., Gallo, E., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.08.010 · Cited by 71 · see citing works

The Pleiotropic Role of the KEAP1/NRF2 Pathway in Cancer

Wu, W., & Papagiannakopoulos, T. Y. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055627 · Cited by 68 · see citing works

Integrative omics identifies conserved and pathogen-specific responses of sepsis-causing bacteria

Mu, A., Klare, W. P., Baines, S. L., Pang, C. N. I., Guérillot, R., Harbison-Price, N., Keller, N., Wilksch, J. J., Nhu, N. T. K., Phan, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37200-w · Cited by 65 · see citing works

The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?

Lamberti, G., Sisi, M., Andrini, E., Palladini, A., Giunchi, F., Lollini, P., Ardizzoni, A., & Gelsomino, F. (2020) · Cancers · doi:10.3390/cancers12113129 · Cited by 64 · see citing works

Geldanamycin-Derived HSP90 Inhibitors Are Synthetic Lethal with NRF2

Baird, L., Suzuki, T., Takahashi, Y., Hishinuma, E., Saigusa, D., & Yamamoto, M. (2020) · Molecular and Cellular Biology · doi:10.1128/mcb.00377-20 · Cited by 37 · see citing works

Nrf2 deficiency aggravates Angiotensin II-induced cardiac injury by increasing hypertrophy and enhancing IL-6/STAT3-dependent inflammation

Chen, D., Li, Z., Bao, P., Chen, M., Zhang, M., Yan, F., Xu, Y., Ji, C., Hu, X., Sanchı́s, D., et al. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.01.020 · Cited by 55 · see citing works

“Keaping” a lid on lung cancer: the Keap1-Nrf2 pathway

Best, S. A., & Sutherland, K. D. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1496756 · Cited by 54 · see citing works

Function of hTim8a in complex IV assembly in neuronal cells provides insight into pathomechanism underlying Mohr-Tranebjærg syndrome

Kang, Y., Anderson, A. J., Jackson, T. D., Palmer, C. S., Souza, D. P. D., Fujihara, K. M., Stait, T. L., Frazier, A. E., Clemons, N. J., Tull, D., et al. (2019) · eLife · doi:10.7554/elife.48828 · Cited by 54 · see citing works

4-Octyl Itaconate Regulates Immune Balance by Activating Nrf2 and Negatively Regulating PD-L1 in a Mouse Model of Sepsis

Zhang, P., Wang, Y., Yang, W., Yin, Y., Li, C., Ma, X., Shi, L., Li, R., & Tao, K. (2022) · International Journal of Biological Sciences · doi:10.2139/ssrn.4045961 · Cited by 51 · see citing works

Distinct Nrf2 Signaling Thresholds Mediate Lung Tumor Initiation and Progression

DeBlasi, J. M., Falzone, A., Caldwell, S., Prieto-Farigua, N., Prigge, J. R., Schmidt, E. E., Chio, I. I. C., Karreth, F. A., & DeNicola, G. M. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3848 · Cited by 49 · see citing works

Proteomic and Metabolomic Signatures Associated With the Immune Response in Healthy Individuals Immunized With an Inactivated SARS-CoV-2 Vaccine

Wang, Y., Wang, X., Luu, L. D. W., Chen, S., Fu, J. X., Wang, S., Huang, X., Wang, L., Zhou, X., Chen, X., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.848961 · Cited by 48 · see citing works

ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis

Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R. D., Townley, S. L., Dehairs, J., Mah, C. Y., Helm, M., Alizadeh‐Ghodsi, M., Pickering, M. A., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-1489 · Cited by 49 · see citing works

Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma

Li, N., Wang, J., & Zhan, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.752643 · Cited by 47 · see citing works

Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC

Garassino, M. C., Gadgeel, S. M., Novello, S., Halmos, B., Felip, E., Speranza, G., Hui, R., Garon, E. B., Horinouchi, H., Sugawara, S., et al. (2022) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100431 · Cited by 47 · see citing works

USP19 exacerbates lipogenesis and colorectal carcinogenesis by stabilizing ME1

Zhu, Y., Gu, L., Lin, X., Zhou, X., Lu, B., Liu, C., Lei, C., Zhou, F., Zhao, Q., Prochownik, E. V., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110174 · Cited by 46 · see citing works

A pan-cancer analysis shows immunoevasive characteristics in NRF2 hyperactive squamous malignancies

Härkönen, J., Pölönen, P., Deen, A. J., Selvarajan, I., Teppo, H., Dimova, E. Y., Kietzmann, T., Ahtiainen, M., Väyrynen, J. P., Väyrynen, S. A., et al. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102644 · Cited by 46 · see citing works

Oncogenic Activation of Nrf2, Though as a Master Antioxidant Transcription Factor, Liberated by Specific Knockout of the Full-Length Nrf1α that Acts as a Dominant Tumor Repressor

Qiu, L., Wang, M., Hu, S., Ru, X., Ren, Y., Zhang, Z., Yu, S., & Zhang, Y. (2018) · Cancers · doi:10.3390/cancers10120520 · Cited by 46 · see citing works

Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Inhibition: An Emerging Strategy in Cancer Therapy

Jiang, Z., Lu, M., & You, Q. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01121 · Cited by 45 · see citing works

Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: Do they have a role in non-oncogene-addicted non-small cell lung cancer?

Popat, S., Grohé, C., Corral, J., Reck, M., Novello, S., Gottfried, M., Radonjic, D., & Kaiser, R. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.04.009 · Cited by 42 · see citing works

Mutational Activation of the NRF2 Pathway Upregulates Kynureninase Resulting in Tumor Immunosuppression and Poor Outcome in Lung Adenocarcinoma

Fahrmann, J. F., Tanaka, I., Irajizad, E., Mao, X., Dennison, J. B., Murage, E. N., Casabar, J. P., Mayo, J., Peng, Q., Çeliktaş, M., et al. (2022) · Cancers · doi:10.3390/cancers14102543 · Cited by 42 · see citing works

Determinants of immunological evasion and immunocheckpoint inhibition response in non-small cell lung cancer: the genetic front

Saigí, M., Alburquerque-Béjar, J. J., & Sánchez‐Céspedes, M. (2019) · Oncogene · doi:10.1038/s41388-019-0855-x · Cited by 41 · see citing works

Metabolic Adaptation-Mediated Cancer Survival and Progression in Oxidative Stress

Tang, Y., Zhang, Z., Chen, Y., Qin, S., Zhou, L., Gao, W., & Shen, Z. (2022) · Antioxidants · doi:10.3390/antiox11071324 · Cited by 41 · see citing works

Nrf2 in TIME: The Emerging Role of Nuclear Factor Erythroid 2-Related Factor 2 in the Tumor Immune Microenvironment

Feng, J., Read, O. J., & Dinkova‐Kostova, A. T. (2023) · Molecules and Cells · doi:10.14348/molcells.2023.2183 · Cited by 41 · see citing works

The Multi-Faceted Consequences of NRF2 Activation throughout Carcinogenesis

Occhiuto, C. J., Moerland, J. A., Leal, A. S., Gallo, K. A., & Liby, K. T. (2023) · Molecules and Cells · doi:10.14348/molcells.2023.2191 · Cited by 40 · see citing works

The multifaceted role of NRF2 in cancer progression and cancer stem cells maintenance

Choi, B.-H., Kim, J. M., & Kwak, M. (2021) · Archives of Pharmacal Research · doi:10.1007/s12272-021-01316-8 · Cited by 40 · see citing works

STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP)

de Lima, V. C. C., Corassa, M. P., Saldanha, E. F., Freitas, H., Arrieta, O. G., Raez, L. E., Samtani, S., Ramos-Ramírez, M., Rojas, C., Burotto, M., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.06.010 · Cited by 38 · see citing works

Implementation of CRISPR/Cas9 Genome Editing to Generate Murine Lung Cancer Models That Depict the Mutational Landscape of Human Disease

Hartmann, O., Reissland, M., Maier, C. R., Fischer, T., Prieto‐Garcia, C., Baluapuri, A., Schwarz, J. D., Schmitz, W., Garrido‐Rodríguez, M., Pahor, N., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.641618 · Cited by 38 · see citing works

Emerging Role of NRF2 Signaling in Cancer Stem Cell Phenotype

Hallis, S. P., Kim, J. M., & Kwak, M. (2023) · Molecules and Cells · doi:10.14348/molcells.2023.2196 · Cited by 37 · see citing works

The Circular RNA Landscape of Non-Small Cell Lung Cancer Cells

Steen, N. V. D., Lyu, Y., Hitzler, A. K., Becker, A. C., Seiler, J., & Diederichs, S. (2020) · Cancers · doi:10.3390/cancers12051091 · Cited by 36 · see citing works

Echinacoside exerts anti-tumor activity via the miR-503-3p/TGF-β1/Smad aixs in liver cancer

Li, W., Zhou, J., Zhang, Y., Zhang, J., Li, X., Yan, Q., Han, J., & Hu, F. (2021) · Cancer Cell International · doi:10.1186/s12935-021-01890-3 · Cited by 36 · see citing works

Research Progress of Plant-Derived Natural Products against Drug-Resistant Cancer

Liu, W., Wang, Y., Xia, L., & Li, J. (2024) · Nutrients · doi:10.3390/nu16060797 · Cited by 35 · see citing works

Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer

van de Haar, J., Mankor, J. M., Hummelink, K., Monkhorst, K., Smit, E. F., Wessels, L. F. A., Cuppen, E. P. J. G., Aerts, J. G. J. V., & Voest, E. E. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-4027 · Cited by 34 · see citing works

Molecular mechanisms and systemic targeting of NRF2 dysregulation in cancer

Kang, J.-S., Nam, L. B., Yoo, O.-K., & Keum, Y. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114002 · Cited by 34 · see citing works

Outcomes in patients treated with frontline immune checkpoint inhibition (ICI) for advanced NSCLC with KRAS mutations and STK11/KEAP1 comutations across PD-L1 levels

Sun, L., Handorf, E. A., Zhou, Y., Borghaei, H., Aggarwal, C., & Bauman, J. R. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107510 · Cited by 33 · see citing works

Genetic drivers of tumor microenvironment and immunotherapy resistance in non-small cell lung cancer: the role of KEAP1 , SMARCA4 , and PTEN mutations

Paredes, R., Borea, R., Drago, F., Russo, A., Nigita, G., & Rolfo, C. D. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012288 · Cited by 32 · see citing works

NRF2 immunobiology in cancer: implications for immunotherapy and therapeutic targeting

Panda, H., Rowland, N. G., Krall, C. M., Bowman, B. M., Major, M. B., & Zolkind, P. (2025) · Oncogene · doi:10.1038/s41388-025-03560-4 · Cited by 35 · see citing works

Current and future biomarkers for outcomes with immunotherapy in non-small cell lung cancer

Duchemann, B., Remón, J., Naigeon, M., Cassard, L., Jouniaux, J.-M., Boselli, L., Grivel, J., Auclin, É., Desnoyer, A., Besse, B., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-839 · Cited by 32 · see citing works

SPP1 overexpression is associated with poor outcomes in ALK fusion lung cancer patients without receiving targeted therapy

Ji, X., Liu, Y., Mei, F., Li, X., Zhang, M., Yao, B., Wu, R., You, J., & Pei, F. (2021) · Scientific Reports · doi:10.1038/s41598-021-93484-2 · Cited by 29 · see citing works

Modulation of NRF2: Biological Dualism in Cancer, Targets and Possible Therapeutic Applications

Gallorini, M., Carradori, S., Panieri, E., Sova, M., & Saso, L. (2023) · Antioxidants and Redox Signaling · doi:10.1089/ars.2022.0213 · Cited by 29 · see citing works

Identification and integration analysis of a novel prognostic signature associated with cuproptosis-related ferroptosis genes and relevant lncRNA regulatory axis in lung adenocarcinoma

Wang, T., Jiang, X., Lü, Y., Ruan, Y., & Wang, J. (2023) · Aging · doi:10.18632/aging.204561 · Cited by 28 · see citing works

The antioxidant response in Barrett's tumorigenesis: A double-edged sword

Peng, D., Zaika, A. I., Que, J., & El-Rifai, W. M. (2021) · Redox Biology · doi:10.1016/j.redox.2021.101894 · Cited by 28 · see citing works

The Comprehensive “Omics” Approach from Metabolomics to Advanced Omics for Development of Immune Checkpoint Inhibitors: Potential Strategies for Next Generation of Cancer Immunotherapy

Yoon, S. J., Lee, C.-B., Chae, S. U., Jo, S., & Bae, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136932 · Cited by 19 · see citing works

Identifying CpG methylation signature as a promising biomarker for recurrence and immunotherapy in non–small-cell lung carcinoma

Luo, R., Song, J., Xiao, X., Xie, Z., Zhao, Z., Zhang, W., Miao, S., Tang, Y., & Ran, L. (2020) · Aging · doi:10.18632/aging.103517 · Cited by 27 · see citing works

Cancer Cell-Intrinsic Alterations Associated with an Immunosuppressive Tumor Microenvironment and Resistance to Immunotherapy in Lung Cancer

Otegui, N., Houry, M., Arozarena, I., Serrano, D., Redín, E., Expósito, F., León, S., Valencia, K., Montuenga, L. M., & Calvo, A. (2023) · Cancers · doi:10.3390/cancers15123076 · Cited by 26 · see citing works

KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer

Galán‐Cobo, A., Vokes, N. I., Qian, Y., Molkentine, D. P., Ramkumar, K., Paula, A. G., Pisegna, M. A., McGrail, D. J., Poteete, A., Cho, S.-N., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.06.011 · Cited by 27 · see citing works

Novel NRF2 ‐activated cancer treatments utilizing synthetic lethality

Baird, L., Kensler, T. W., & Yamamoto, M. P. (2022) · IUBMB Life · doi:10.1002/iub.2680 · Cited by 26 · see citing works

A NRF2-induced secretory phenotype activates immune surveillance to remove irreparably damaged cells

Baird, L., Taguchi, K., Zhang, A., Takahashi, Y., Suzuki, T., Kensler, T. W., & Yamamoto, M. P. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102845 · Cited by 26 · see citing works

Isovalerylspiramycin I suppresses non-small cell lung carcinoma growth through ROS-mediated inhibition of PI3K/AKT signaling pathway

Liu, Z., Huang, M., Hong, Y., Wang, S., Xu, Y., Zhong, C., Zhang, J., Zhuang, Z., Shan, S., & Ren, T. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.69989 · Cited by 25 · see citing works

Clinicopathological, microenvironmental and genetic determinants of molecular subtypes in KEAP1/NRF2‐mutant lung cancer

Cai, M., Chen, M., Ma, P., Wu, J., Lu, H., Zhang, S., Liu, J., Zhao, X., Zhuang, G., Yu, Z., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31975 · Cited by 25 · see citing works

Immune Modulation in Lung Cancer: Current Concepts and Future Strategies

Gaissmaier, L., & Christopoulos, P. (2020) · Respiration · doi:10.1159/000510385 · Cited by 24 · see citing works

BRD4 Targets the KEAP1-Nrf2-G6PD Axis and Suppresses Redox Metabolism in Small Cell Lung Cancer

Lv, Y., Lv, X., Zhang, J., Cao, G., Xu, C., Zhang, B., & Lin, W. (2022) · Antioxidants · doi:10.3390/antiox11040661 · Cited by 23 · see citing works

PO-210 Synergy between the KEAP1/NRF2 and PI3K pathways drives non-small cell lung cancer with an altered metabolism

Best, S. A., DeSouza, D., Kersbergen, A. J., Dayalan, S., Tull, D., Policheni, A. N., Gray, D. H. D., Ritchie, M. E., McConville, M. J., & Sutherland, K. D. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-eacr25.728 · Cited by 1 · see citing works

MA24.09 Synergy Between the KEAP1/NRF2 and PI3K Pathways Drives Non-Small Cell Lung Cancer with an Altered Metabolism

Best, S. A., Desouza, D., Kersbergen, A. J., Policheni, A. N., Dayalan, S., Tull, D., Rathi, V., Gray, D. H. D., Ritchie, M. E., McConville, M. J., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.08.526

Battles against aberrant KEAP1-NRF2 signaling in lung cancer: intertwined metabolic and immune networks

Xu, K., Ma, J., Hall, S. R. R., Peng, R., Yang, H., & Yao, F. (2023) · Theranostics · doi:10.7150/thno.80184 · Cited by 75 · see citing works

Synergy Between the KEAP1/NRF2 and PI3K Pathways Drives Non-Small Cell Lung Cancer with an Altered Metabolism

Best, S. A., Souza, D. P. D., Kersbergen, A. J., Policheni, A. N., Dayalan, S., Tull, D., Rathi, V., Gray, D. H. D., Ritchie, M. E., Mcconyille, M., et al. (2018) · Journal of Thoracic Oncology

KEAP1-Mutant NSCLC: The Catastrophic Failure of a Cell-Protecting Hub

Scalera, S., Mazzotta, M., Cortile, C., Krasniqi, E., Maria, R. D., Cappuzzo, F., Ciliberto, G., & Maugeri‐Saccà, M. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.03.011 · Cited by 74 · see citing works